CO2021006869A2 - Anticuerpos humanizados contra c-kit - Google Patents
Anticuerpos humanizados contra c-kitInfo
- Publication number
- CO2021006869A2 CO2021006869A2 CONC2021/0006869A CO2021006869A CO2021006869A2 CO 2021006869 A2 CO2021006869 A2 CO 2021006869A2 CO 2021006869 A CO2021006869 A CO 2021006869A CO 2021006869 A2 CO2021006869 A2 CO 2021006869A2
- Authority
- CO
- Colombia
- Prior art keywords
- kit
- antibodies against
- humanized antibodies
- antibodies
- methods
- Prior art date
Links
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención proporciona anticuerpos que se unen específicamente a c-Kit y métodos para usar dichos anticuerpos en la sustitución de células madre y el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771526P | 2018-11-26 | 2018-11-26 | |
| PCT/US2019/063091 WO2020112687A2 (en) | 2018-11-26 | 2019-11-25 | Humanized antibodies against c-kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021006869A2 true CO2021006869A2 (es) | 2021-06-10 |
Family
ID=70769872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0006869A CO2021006869A2 (es) | 2018-11-26 | 2021-05-25 | Anticuerpos humanizados contra c-kit |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11208482B2 (es) |
| EP (2) | EP4442278A3 (es) |
| JP (2) | JP7166457B2 (es) |
| KR (1) | KR20210094610A (es) |
| CN (2) | CN113194991B (es) |
| AU (2) | AU2019386976B2 (es) |
| CA (1) | CA3117816A1 (es) |
| CL (1) | CL2021001366A1 (es) |
| CO (1) | CO2021006869A2 (es) |
| CR (1) | CR20210272A (es) |
| DO (1) | DOP2021000101A (es) |
| EA (1) | EA202190986A1 (es) |
| ES (1) | ES2988145T3 (es) |
| IL (1) | IL282668A (es) |
| MX (1) | MX2021006134A (es) |
| MY (1) | MY205760A (es) |
| PE (1) | PE20211786A1 (es) |
| PH (1) | PH12021551126A1 (es) |
| PL (1) | PL3817773T3 (es) |
| PT (1) | PT3817773T (es) |
| SA (1) | SA521422089B1 (es) |
| SG (1) | SG11202104441QA (es) |
| SI (1) | SI3817773T1 (es) |
| UA (1) | UA128431C2 (es) |
| WO (1) | WO2020112687A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210023831A (ko) | 2018-05-11 | 2021-03-04 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법 |
| SG11202104441QA (en) | 2018-11-26 | 2021-06-29 | Forty Seven Inc | Humanized antibodies against c-kit |
| US20220023348A1 (en) | 2018-11-28 | 2022-01-27 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
| AU2020283811A1 (en) * | 2019-05-24 | 2021-12-16 | Forty Seven, Inc. | Regimes for co-administration of immunotherapeutic agents against c-kit and CD47 |
| CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| IL305088A (en) * | 2021-02-09 | 2023-10-01 | Jasper Therapeutics Inc | Different stem cell composition and methods of use |
| US20240409603A1 (en) * | 2021-10-18 | 2024-12-12 | Jasper Therapeutics, Inc. | Modified stem cell compositions and methods for use |
| IL313568A (en) | 2021-12-16 | 2024-08-01 | Universit?T Basel | Discernible cell surface protein variants of cd117 for use in cell therapy |
| KR102572039B1 (ko) * | 2022-04-18 | 2023-08-30 | 주식회사 노벨티노빌리티 | 슈도모나스 외독소 A를 포함하는 c-Kit 표적 면역접합체 |
| CN119343377A (zh) * | 2022-06-09 | 2025-01-21 | 圣塔安娜生物股份有限公司 | 靶向c-Kit和/或siglec的抗体及其用途 |
| KR20250034296A (ko) | 2022-07-07 | 2025-03-11 | 씨메이오 테라퓨틱스 아게 | Cd117을 표적화하는 항체 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024131861A1 (en) * | 2022-12-21 | 2024-06-27 | Erasmus University Medical Center Rotterdam | Bispecific antibodies targeting cd117 and cd3 |
| US20240398982A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5821108A (en) | 1995-04-07 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| CA2361492A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| JP4344325B2 (ja) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法 |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| DK1820022T3 (da) | 2004-11-10 | 2009-09-14 | Boehringer Ingelheim Pharma | Anvendelse af flow-cytometrisk analyse for at optimere cellebanks-strategier af CHO-celler |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| CN101528744A (zh) | 2006-10-20 | 2009-09-09 | Irm责任有限公司 | 用于调节c-kit和pdgfr受体的组合物和方法 |
| EP3255061B1 (en) | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
| CA2677925A1 (en) | 2007-03-02 | 2008-09-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improvement of protein production comprising increasing the expression or activity of cert |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| JP5547656B2 (ja) | 2008-01-15 | 2014-07-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| EP4470556A2 (en) | 2008-01-15 | 2024-12-04 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2435067A2 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Stem cell targeting |
| EP4134095A1 (en) | 2009-09-15 | 2023-02-15 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| US20120283124A1 (en) | 2009-11-10 | 2012-11-08 | Park Christopher Y | Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes |
| EP2569013B1 (en) | 2010-05-14 | 2016-11-23 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| PT2804611T (pt) | 2012-01-20 | 2020-11-12 | Immunophotonics Inc | Composições derivadas da quitosana |
| DK3381943T3 (da) * | 2012-07-25 | 2022-05-16 | Celldex Therapeutics Inc | Anti-kit-antistoffer og anvendelser deraf |
| JP6255408B2 (ja) | 2012-09-25 | 2017-12-27 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 治療システム |
| WO2014138449A1 (en) * | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| MA38396B1 (fr) | 2013-03-15 | 2019-05-31 | Novartis Ag | Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit |
| AR100280A1 (es) * | 2014-05-22 | 2016-09-21 | Rohm & Haas | Aglutinantes poliméricos para impresoras de chorro de tinta |
| US10786578B2 (en) * | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| EP3822364B1 (en) | 2014-08-26 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
| IL287952B2 (en) | 2015-04-06 | 2024-11-01 | Harvard College | Compositions and methods for non-myeloablative conditioning |
| WO2016179399A1 (en) | 2015-05-06 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity cd47 analogs |
| JP7064234B2 (ja) | 2015-05-18 | 2022-05-10 | エービー イニチオ バイオセラピューティクス，インク． | Ｓｉｒｐポリペプチド組成物および使用の方法 |
| KR102505253B1 (ko) | 2016-04-15 | 2023-03-02 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 |
| BR112018076306A2 (pt) | 2016-06-17 | 2019-03-26 | Magenta Therapeutics, Inc. | composições e métodos para a supressão de células cd117+ |
| IL265692B2 (en) | 2016-09-29 | 2024-03-01 | Amgen Inc | Low viscosity antigen binding proteins and methods for their preparation |
| JOP20190155A1 (ar) | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم |
| BR112019015342A2 (pt) | 2017-01-30 | 2020-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Regime de condicionamento não genotóxico para o transplante de células-tronco |
| US20200199247A1 (en) | 2017-06-07 | 2020-06-25 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
| WO2018237168A1 (en) | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | DOSING PARAMETERS FOR CD47 TARGETING THERAPIES WITH HEMATOLOGICAL MALIGNANCIES |
| CN111448210B (zh) | 2017-07-26 | 2024-05-14 | 四十七公司 | 抗SIRP-α抗体及相关方法 |
| SG11202104441QA (en) * | 2018-11-26 | 2021-06-29 | Forty Seven Inc | Humanized antibodies against c-kit |
| US20220023348A1 (en) | 2018-11-28 | 2022-01-27 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
| AU2020283811A1 (en) | 2019-05-24 | 2021-12-16 | Forty Seven, Inc. | Regimes for co-administration of immunotherapeutic agents against c-kit and CD47 |
-
2019
- 2019-11-25 SG SG11202104441QA patent/SG11202104441QA/en unknown
- 2019-11-25 JP JP2021529294A patent/JP7166457B2/ja active Active
- 2019-11-25 US US16/694,975 patent/US11208482B2/en active Active
- 2019-11-25 PT PT198900961T patent/PT3817773T/pt unknown
- 2019-11-25 CN CN201980077493.XA patent/CN113194991B/zh active Active
- 2019-11-25 EP EP24190375.6A patent/EP4442278A3/en active Pending
- 2019-11-25 ES ES19890096T patent/ES2988145T3/es active Active
- 2019-11-25 WO PCT/US2019/063091 patent/WO2020112687A2/en active Application Filing
- 2019-11-25 CR CR20210272A patent/CR20210272A/es unknown
- 2019-11-25 MX MX2021006134A patent/MX2021006134A/es unknown
- 2019-11-25 MY MYPI2021002888A patent/MY205760A/en unknown
- 2019-11-25 KR KR1020217019482A patent/KR20210094610A/ko active Pending
- 2019-11-25 AU AU2019386976A patent/AU2019386976B2/en active Active
- 2019-11-25 UA UAA202102764A patent/UA128431C2/uk unknown
- 2019-11-25 EA EA202190986A patent/EA202190986A1/ru unknown
- 2019-11-25 PE PE2021000758A patent/PE20211786A1/es unknown
- 2019-11-25 EP EP19890096.1A patent/EP3817773B1/en active Active
- 2019-11-25 SI SI201930800T patent/SI3817773T1/sl unknown
- 2019-11-25 CA CA3117816A patent/CA3117816A1/en active Pending
- 2019-11-25 CN CN202411511840.4A patent/CN119684457A/zh active Pending
- 2019-11-25 PL PL19890096.1T patent/PL3817773T3/pl unknown
-
2020
- 2020-12-29 US US17/137,228 patent/US11041022B2/en active Active
-
2021
- 2021-04-26 IL IL282668A patent/IL282668A/en unknown
- 2021-05-17 PH PH12021551126A patent/PH12021551126A1/en unknown
- 2021-05-24 SA SA521422089A patent/SA521422089B1/ar unknown
- 2021-05-25 DO DO2021000101A patent/DOP2021000101A/es unknown
- 2021-05-25 CL CL2021001366A patent/CL2021001366A1/es unknown
- 2021-05-25 CO CONC2021/0006869A patent/CO2021006869A2/es unknown
- 2021-11-17 US US17/528,976 patent/US12091458B2/en active Active
-
2022
- 2022-07-13 JP JP2022112548A patent/JP2022137208A/ja not_active Withdrawn
-
2024
- 2024-08-08 AU AU2024205621A patent/AU2024205621A1/en active Pending
- 2024-08-12 US US18/801,074 patent/US20250034246A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000101A (es) | Anticuerpos humanizados contra c-kit | |
| CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| CY1123065T1 (el) | Ανασυνδυασμενα προβιοτικα βακτηριδια | |
| EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
| ECSP17070399A (es) | Anticuerpos contra icos | |
| MX2024008096A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| CL2020000060A1 (es) | Compuestos antiproliferativos y métodos para utilizarlos. | |
| CO2020014345A2 (es) | Anticuerpos específicos para gucy2c y sus usos | |
| PE20210289A1 (es) | Anti-cd25 para el agotamiento de celulas tumorales especificas | |
| AR113862A1 (es) | Anticuerpos anti-cd47 y sus usos para tratar cáncer | |
| UY37779A (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| BR112017018954A2 (pt) | uso de forma mutante de proteína ras e método para tratar câncer | |
| ECSP17005276A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| AR101697A1 (es) | Terapia de combinación de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana | |
| BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
| PE20171556A1 (es) | Agentes de union a cd123 y usos de estos | |
| UY35417A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| CR20190417A (es) | Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| MX2020003783A (es) | Moleculas de anticuerpo de cd138 y sus usos. | |
| MX373818B (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| MX2021016098A (es) | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. |